Pasithea Therapeutics Corp. - Common Stock (NQ: KTTA )
1.787
-0.123
(-6.44%)
Streaming Delayed Price
Updated: 10:08 AM EST, Feb 10, 2025
Add to My Watchlist
All News about Pasithea Therapeutics Corp. - Common Stock
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/premkt_movers_494.png)
24 Stocks Moving in Thursday's Pre-Market Session
November 18, 2021
Via Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
November 17, 2021
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2021/movers_image_4493.jpeg)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/photo_science_in_hd_on_unsplash.jpg?width=720)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/pexels-photo-7659683.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/pexels-photo-9853003.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2021/movers_image_3652.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_321.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/screenshot_2021-11-01_at_1.04.39_pm.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2021/movers_image_3479.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/premkt_movers_480.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/brain-g3ac806736_640.jpg)
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
October 27, 2021
Exposures
Product Safety
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/intravenous_therapy_2007-sep-13-singapore.jpg?width=720)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/psyched_cover_ver_2_6.jpg?width=720)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/pexels-cottonbro-7578803.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
Rising Acceptance For Treating Mental Disorders is Fueling Strong Growth in Psychedelic Drugs Market
October 14, 2021
Exposures
COVID-19
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/brain-1787622_1920_80.jpg?width=720)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/pexels-anna-nekrashevich-6801874_4.jpg?width=720)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/photo-1582560475052-682d1beb5f42.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_2169.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/biotech_3.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_378.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/laboratory-2815640_1920_1_12.jpg)
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.